Niramai vs PathAI

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Niramai employs 50-200 people, while PathAI has 300 employees.

PathAI has raised more in total funding at $255M, compared to Niramai's $17M — a gap of $238M. Combined, the two companies have completed 3 known funding rounds.

PathAI holds the higher Awaira Score at 62/100, compared to Niramai's 60/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 2-point gap that reflects meaningful differences in scale or traction.

Niramai was founded by Geetha Manjunath in 2016. PathAI was founded by Andy Beck in 2016. Visit each company's profile on Awaira for a full founder biography.

Niramai: Niramai has developed a radiation-free, non-contact breast cancer screening solution that uses thermal imaging combined with AI-powered image analysis to detect early-stage breast cancer, addressing the significant access and cost barriers that prevent widespread mammography screening in low- and middle-income countries. The technology works without X-ray radiation, requires no radiologist for initial interpretation, and can be deployed in mobile screening units.\n\nThe company raised approximately $17M in Series B funding and has conducted clinical validation studies demonstrating sensitivity and specificity metrics competitive with mammography for early detection. Niramai has deployed its screening solution at hospitals, corporate wellness programs, and rural health camps across India.\n\nBreast cancer is the most common cancer among Indian women, yet screening rates remain critically low due to equipment costs, specialist shortages, and cultural barriers to mammography. Niramai's AI-powered thermal screening addresses each of these barriers simultaneously, positioning the company at the intersection of AI healthcare innovation and a major Indian public health challenge. PathAI: PathAI is an AI healthcare company founded in 2016 that develops digital pathology solutions and AI-powered diagnostic tools for pathology labs and healthcare institutions. The company specializes in machine learning algorithms designed to assist pathologists in analyzing tissue samples and identifying diseases, particularly cancer. PathAI's core technology platform leverages deep learning and computer vision to process histopathology images, enhancing diagnostic accuracy and workflow efficiency. The company's primary offering includes software that integrates with existing laboratory information systems, enabling pathologists to use AI-assisted analysis for specimen evaluation. PathAI has developed partnerships with major healthcare systems and diagnostic laboratories, demonstrating clinical utility in oncology and other pathology specialties. The platform addresses critical challenges in pathology including diagnostic consistency, workload management, and access to specialized expertise in underserved regions. PathAI has raised $255 million in total funding as of its Series C stage, with valuation not disclosed. The company operates in the competitive digital pathology and AI diagnostics space, alongside competitors offering similar computational pathology solutions. The digital pathology market is experiencing significant growth driven by increasing diagnostic demands, laboratory automation trends, and regulatory acceptance of AI-assisted tools. PathAI's trajectory reflects broader momentum in AI-enabled healthcare diagnostics and precision medicine applications. PathAI combines deep learning with pathology workflows to create clinically integrated AI tools that assist rather than replace human pathologists.

Both Niramai and PathAI were founded in the same year — 2016. Despite sharing a founding year, they may have launched at different times within that year, which can matter in fast-moving AI markets.

Niramai has approximately 50-200 employees, while PathAI has approximately 300. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Niramai and PathAI are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.